Are peptides legal in Australia? The complete 2025 regulatory guide

Most therapeutic peptides in Australia are Schedule 4 (prescription-only) medicines under the TGA's Poisons Standard. This means they are legal to possess and use — but only when prescribed by an AHPRA-registered medical practitioner and dispensed by a licensed Australian compounding pharmacy. Purchasing them without a prescription or importing from overseas without authorisation is not compliant with Australian law.

Prior to 2023, a grey market of domestic 'research use only' suppliers operated in Australia. In 2023, the TGA significantly tightened enforcement — the outgoing TGA head noted a $10 million court case win against peptides sold online with no medical doctor involvement. Domestic research chemical suppliers largely ceased operations following this enforcement action.

Schedule 4 (prescription-only) classification applies to: BPC-157, TB-500, Ipamorelin, CJC-1295, Sermorelin, AOD-9604, Semaglutide, and PT-141. Schedule 4 means these substances are legal to use in Australia only when prescribed by an AHPRA-registered medical practitioner and dispensed by a TGA-licensed compounding pharmacy using approved starting materials.

Because most peptides are not registered therapeutic goods, they are accessed via the compounding exemption. A registered doctor assesses the patient, determines clinical need, and writes a prescription. The prescription is filled by a licensed compounding pharmacy, which manufactures the peptide to order using pharmaceutical-grade raw materials. This is the only fully compliant pathway for peptide access in Australia.

Every protocol on ProtocolHub includes guidance on the Australian legal pathway for that compound. We only recommend providers who use AHPRA-registered clinicians and TGA-licensed compounding pharmacies. If you are considering peptide therapy, start with a telehealth consultation from one of our vetted clinic partners — the prescription pathway is simpler than most people expect.